Tests glutamate infusion to prevent kidney injury after heart bypass surgery
Tests glutamate given through a vein to prevent kidney injury in adults without diabetes.
Plain-language title generated from the registry record
Registry title: GLUTAMICS III
Key facts
- Where
- Goteborg, Linkoping, Lund, Orebro, and Uppsala, SwedenSee the 5 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults without diabetes who are having heart bypass surgery (CABG) with a heart-lung machine and who have a high risk of kidney injury afterwards.
- Age
- 18 years or older, up to 85 years.
- Sex
- All sexes can join.
- Disease stage
- Coronary artery disease affecting at least two vessels or the left main artery. High risk means EuroSCORE II of 3.0 or more plus at least one cardiac or procedure-related risk factor, or a heart pumping fraction (Left Ventricular Ejection Fraction) of 0.30 or less.
- Earlier treatment
- No previous heart surgery.
Main reasons for not taking part
- Diabetes
- Previous heart surgery
- Dialysis before surgery or creatinine clearance below 30 mL/min
- Needing medicines or a device to support the heart before surgery
- Surgery without a heart-lung machine (off-pump)
Read by machine on 9 November 2026.
Where in Sweden
- Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenNot yet recruiting
- Region OestergoetlandLinkoping, SwedenNot yet recruiting
- Region Skane Skanes UniversitetssjukhusLund, SwedenNot yet recruiting
- Region Oerebro LaenOrebro, SwedenNot yet recruiting
- Uppsala University HospitalUppsala, SwedenNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Oestergoetland
- Trial code
- EU 2024-513575-40-01
- Record updated
- 4 June 2026
- Original description
To establish the efficacy of intravenous glutamate infusion to prevent acute kidney injury (AKI) after coronary artery bypass surgery (CABG) among high-risk patients without diabetes.Read full original descriptionShow less
Glutamate infusion for prevention of Acute Kidney Injury in surgery for ischemic heart disease: (GLUTAMICS III = GLUTAmate for Metabolic Intervention in Coronary Surgery III)
To establish the efficacy of intravenous glutamate infusion to prevent acute kidney injury (AKI) after coronary artery bypass surgery (CABG) among high-risk patients without diabetes.
Inclusion: Adult patients without diabetes operated on heart-lung machine with CABG of at least two vessel disease or left main stenosis with or without a concomitant procedure and who either have EuroSCORE II ≥ 3.0 to which at least one cardiac or procedure related risk factor contribute or Left Ventricular Ejection Fraction ≤ 0.30 regardless of EuroSCORE II.
Exclusion: Diabetes; ambiguous food allergy known to have elicited flushing, headache, rash or asthma; age > 85 years; previous cardiac surgery; informed consent not possible because of critical condition or other reason; preoperative use of inotropic support or mechanical circulatory assist; preoperative dialysis or calculated Creatinine clearance < 30 mL/min; surgery without heart-lung machine (off-pump); concomitant Maze-procedure; surgery of ascending aorta necessitating circulatory arrest; surgery of both aortic and mitral valve.